OakChart

Cardiff Oncology Inc

CRDFHealthcare·Biotechnology·USA·Micro·NASD·Nov 11 • 10:02 AM ET

0.7790-0.0158 (-1.99%)
2026-11-11 16:03 CET
Market cap
61.83 USD m
Revenue, TTM
0.51 USD m
Net income, TTM
-40.08 USD m
Free cash flow, TTM
-40.92 USD m
EPS diluted, TTM
-0.59
P/E
-
Compare

Price

CRDF against its 20, 50 and 200-day averages
2050200beatmiss
1.001.502.006.4M12.7MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26CRDFclose 0.7820-day 0.8750-day 1.05200-day 1.360.78

76.5% under 3.31 on 26 Dec 2025. Last 15 sessions, 29.9% high to low

Profile

CRDF
52-week range, 1% of the way up
0.753.31

Cardiff Oncology, Inc. is an oncology therapeutics company, which engages in the development of drugs that target mitosis for the treatment of various types of cancer. The firm is focused on developing onvansertib, a first-in-class, third-generation Polo-like Kinase 1 (PLK1) inhibitor, in combination with standard-of-care chemotherapy and targeted therapeutics. Its clinical programs include KRAS-Mutated Metastatic Colorectal Cancer (mCRC), Resistant Metastatic Castration-Resistant Prostate Cancer (mCRPC) and relapsed or refractory Acute Myeloid Leukemia (AML). The company was founded by Gabriel M. Cerrone, L. David Tomei, Samuil Umansky, and Hovsep Melkonyan in 1999 and is headquartered in San Diego, CA.

Employees31
IPOJul 27, 2004
Beta1.58
ATR, 14d0.07
Rel volume0.22
Short float16.80%
Insider own6.17%
Inst own21.57%

Snapshot

6 groups

Valuation

Index-
Market Cap60.60M
Enterprise Value26.54M
Income-40.08M
Sales0.51M
Book/sh0.39
Cash/sh0.44
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees31
IPOJul 27, 2004

Ratios

P/E-
Forward P/E-
PEG-
P/S118.83
P/B2.01
P/C1.76
P/FCF-
EV/EBITDA-
EV/Sales52.04
Quick Ratio3.30
Current Ratio3.30
Debt/Eq0.02
LT Debt/Eq0.00
Option/ShortYes / Yes

Earnings

EPS (ttm)-0.59
EPS next Y-0.61
EPS next Q-0.14
EPS this Y16.31%
EPS next Y-5.38%
EPS next 5Y-8.14%
EPS past 3/5Y8.24% 8.71%
Sales past 3/5Y15.39% 10.13%
EPS Y/Y TTM32.77%
Sales Y/Y TTM-6.96%
EPS Q/Q35.57%
Sales Q/Q-14.05%
EarningsAug 11 AMC
EPS/Sales Surpr.-17.06% 65.61%

Ownership

Insider Own6.17%
Insider Trans19.30%
Inst Own21.57%
Inst Trans-7.78%
ROA-70.84%
ROE-94.08%
ROIC-150.95%
Gross Margin-75.20%
Oper. Margin-8320.08%
Profit Margin-7888.98%
SMA20-10.17%
SMA50-26.07%
SMA200-42.67%
Trades-

Technical

Shs Outstand77.80M
Shs Float73.00M
Short Float16.80%
Short Ratio19.78
Short Interest12.26M
52W High3.31 -76.47%
52W Low0.75 3.88%
Volatility7.95% 8.62%
ATR (14)0.07
RSI (14)34.62
Beta1.58
Rel Volume0.22
Avg Volume619.87K
Volume17,064

Performance

Perf Week-10.35%
Perf Month-22.87%
Perf Quarter-20.83%
Perf Half Y-53.91%
Perf YTD-72.28%
Perf Year-65.98%
Perf 3Y-22.10%
Perf 5Y-86.19%
Perf 10Y-99.65%
Recom2.33
Target Price5.14
Prev Close0.79
Price0.78
Change %-1.99%

Analyst ratings

latest 10 of 14
DateActionAnalystRating changeTargetImplied
Sep 15, 2026UpgradeHH.C. WainwrightNeutral → Buy$9+1,055.3%
Aug 12, 2026DowngradeWWilliam BlairOutperform → Mkt Perform
Jun 03, 2026DowngradeCCraig HallumBuy → Hold$2+156.7%
Jun 01, 2026DowngradeTTD CowenBuy → Hold
Jun 01, 2026DowngradeHH.C. WainwrightBuy → Neutral
Jan 05, 2026InitiatedNNoble Capital MarketsOutperform$12+1,440.4%
Jul 08, 2025InitiatedLLadenburg ThalmannBuy$19+2,339.0%
Jun 24, 2025InitiatedJJefferiesHold$3.50+349.3%
Sep 06, 2024InitiatedCCraig HallumBuy$8+927.0%
Jan 05, 2022InitiatedWWilliam BlairOutperform

Peers

Mkt cap
TickerCompanyMkt cap
AGENAgenus Inc321.93M
ELTXElicio Therapeutics Inc45.57M
ACRVAcrivon Therapeutics Inc68.25M
ERASErasca Inc5.79B
ONCYOncolytics Biotech Inc48.28M
OKUROnKure Therapeutics Inc138.72M
VSTMVerastem Inc1.13B
BBOTBridgeBio Oncology Therapeutics Inc193.62M
KZIAKazia Therapeutics Limited ADR86.07M
RVMDRevolution Medicines Inc41.25B

Insider trading

4 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
PACE GARY WDirectorJul 14 '26Buy1.46687,2851,000,0002,043,661Jul 16 04:03 PM
Mohindru ManiChief Executive OfficerJul 14 '26Buy1.4634,36450,00059,067Jul 16 04:01 PM
Mohindru ManiChief Executive OfficerJun 18 '26Buy1.2124,70329,89124,703Jun 22 09:00 AM
PACE GARY WDirectorJun 18 '26Buy1.2230,00036,6001,356,376Jun 22 09:00 AM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWCiShares Micro-Cap ETFAUM: 1.22B

News

latest 14 of 206
  • Cardiff Oncology to Participate in the UBS Global Biopharma Conference (GlobeNewswire)
  • Cardiff Oncology Appoints Leila Alland, MD, as Interim Chief Medical Officer (GlobeNewswire) +8.80%
  • Cardiff Oncology Receives FDA Orphan Drug Designation for Onvansertib in Chronic Myelomonocytic Leukemia (GlobeNewswire)
  • Cardiff Oncology and Nerviano Medical Sciences Amend their 2017 Exclusive License Agreement (GlobeNewswire) +8.26%
  • Cardiff Oncology to Participate in September 2026 Conferences (GlobeNewswire)
  • Loading…
  • Cardiff Oncology: Q2 Earnings Snapshot (Associated Press) -5.67%
  • Cardiff Oncology Reports Second Quarter 2026 Results and Provides Business Update (GlobeNewswire)
  • Cardiff Oncology Announces $10 Million Registered Direct Offering to Strengthen Working Capital (InvestorsHub) -32.11%
  • Cardiff Oncology Announces $10 Million Registered Direct Offering (GlobeNewswire)
  • Cardiff Oncology Announces Presentation of Positive Results from its Randomized, Controlled Phase 2 Trial of Onvansertib in First-Line RAS-Mutated mCRC at the 2026 ASCO Annual Meeting (GlobeNewswire)
  • Cardiff Oncology to Participate in the Jefferies Global Healthcare Conference (GlobeNewswire) -22.11%
  • Cardiff Oncology Announces Webcast to Discuss Updated Phase 2 CRDF-004 Data for Onvansertib in First-Line RAS-Mutated mCRC (GlobeNewswire)
  • Cardiff Oncology: Q1 Earnings Snapshot (Associated Press)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-08-11-0.140-0.120-0.1400.100.069
2026Q12026-05-14-0.180-0.135-0.1810.040.098
2025Q42026-02-24-0.110-0.189-0.1060.240.1010
2025Q32025-11-06-0.170-0.205-0.1680.120.138
2025Q22025-07-29-0.210-0.193-0.2100.120.118
2025Q12025-05-08-0.200-0.185-0.2020.110.097
2024Q42025-02-27-0.220-0.246-0.2140.150.106
2024Q32024-11-07-0.250-0.270-0.2530.170.075
2024Q22024-08-08-0.260-0.248-0.2630.160.064
2024Q12024-05-02-0.220-0.249-0.2240.210.064
2023Q42024-02-29-0.210-0.267-0.2090.160.054
2023Q32023-11-02-0.220-0.284-0.2180.140.054
2023Q22023-08-09-0.250-0.261-0.2500.110.055
2023Q12023-05-04-0.250-0.226-0.2510.080.075
2022Q42023-03-02-0.198-0.235-0.1950.110.074
2022Q32022-11-03-0.200-0.264-0.1980.090.075

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-2.800-2.990-2.7970.250.38
2020FY-1.080-1.028-1.0830.370.27
2021FY-0.730-0.663-0.7260.360.22
2022FY-0.890-0.928-0.8880.390.28
2023FY-0.930-0.987-0.9280.490.36
2024FY-0.950-0.988-0.9540.680.62
2025FY-0.690-0.768-0.6900.590.46
2026FY--0.578--0.29
2027FY--0.609--0.32
2028FY--0.873--0.29
2029FY--0.319--130.28
2030FY--0.020--309.76

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-09-147000.080.000.15
2026Q3S2026-09-066000.070.000.14
2026Q3S2026-08-297000.080.000.15
2026Q3S2026-08-278000.080.000.15
2026Q3S2026-08-129000.070.000.15
2026Q3S2026-08-119000.070.000.15
2026Q3S2026-08-049000.070.000.15
2026Q3S2026-07-299010.070.000.15
2026Q3S2026-07-019020.070.000.15
2026Q3S2026-05-219030.070.000.15
2026Q3S2026-05-158020.070.000.15
2026Q3S2026-04-177010.090.000.15
2026Q3S2026-03-257100.100.000.20
2026Q3S2026-02-257000.090.000.15

Estimate history

EPS, annual-51.84-8.263-2.797-1.083-0.726-0.888-0.928-0.954-0.686-0.5905
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.263-0.253-0.214-0.202-0.21-0.168-0.106-0.181-0.135
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual0.5050.3780.2450.3660.3590.3860.4880.6830.5930.51
Period201720182019202020212022202320242025TTM
Sales, quarterly0.1630.1650.1510.1090.1210.120.2430.0410.104
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual0.7333.8328.59436.78141.96444.67744.67766.52468.30568.502
Period201720182019202020212022202320242025MRQ
Shares, quarterly45.60248.73166.52466.52666.52667.09568.30568.3768.502
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.510.590.680.490.390.360.370.240.38
Cost of Goods Sold Incl. D&A0.890.900.400.400.200.50--0.97
Gross Profit-0.38-0.310.280.090.19-0.14---0.59
Selling, General and Administrative Excl. Other41.8848.6548.9345.5040.0928.7118.9516.4315.80
Research and Development25.9535.3336.8532.8627.1117.3811.2411.168.16
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-42.27-48.96-48.65-45.41-39.90-28.86-19.05-16.68-16.39
Interest Expense0.000.000.000.000.000.000.000.000.03
Unusual Expense0.000.000.000.000.00-0.280.32-0.030.03
Net Income Before Taxes-40.05-45.85-45.43-41.44-38.70-28.29-19.31-16.41-16.46
Income Taxes0.000.000.000.000.000.000.000.000.00
Consolidated Net Income-40.05-45.85-45.43-41.44-38.70-28.29-19.31-16.41-16.46
Net Income From Continuing Operations-40.05-45.85-45.43-41.44-38.70-28.29-19.31-16.41-16.46
Net Income-40.08-45.88-45.45-41.47-38.73-28.32-22.60-16.71-19.25
EPS (Recurring)-0.59-0.69-0.95-0.93-0.89-0.73-1.07-2.80-8.25
EPS (Basic, Before Extraordinaries)-0.59-0.69-0.95-0.93-0.89-0.73-1.08-2.80-8.26
EPS (Diluted)-0.59-0.69-0.95-0.93-0.89-0.73-1.08-2.80-8.26
EBITDA-41.38-48.06-48.25-45.01-39.70-28.36-18.59-16.18-15.65
Non-Operating Income (Expense)2.213.113.223.971.200.280.060.24-0.02
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense5.225.694.764.514.263.231.760.882.17
Price To Sales Ratio175.03316.73302.78135.50158.13653.401,026.0730.2819.42
Gross Margin-75.20-52.4540.8518.4448.19-39.28---155.20
Operating Margin-8,320.08-8,256.32-7,123.13-9,305.74-10,337.31-8,037.60-5,205.48-6,817.79-4,331.92
Net Margin-7,888.98-7,736.26-6,655.20-8,496.93-10,033.16-7,887.19-6,174.27-6,829.31-5,089.53
Shares Outstanding68.5068.3166.5244.6844.6841.9636.788.593.83
Market Capitalization61.8361.83288.6966.1262.55252.20635.499.6012.08

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue0.100.040.240.120.120.110.150.17
Cost of Goods Sold Incl. D&A0.220.220.220.220.230.230.100.10
Gross Profit-0.12-0.180.02-0.10-0.11-0.120.060.06
Selling, General and Administrative Excl. Other9.5012.677.8511.8714.6714.2612.6312.66
Research and Development5.926.765.088.2011.5810.489.719.64
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-9.62-12.85-7.83-11.97-14.78-14.38-12.57-12.60
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes-9.23-12.35-7.22-11.26-13.94-13.43-11.79-11.86
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-9.23-12.35-7.22-11.26-13.94-13.43-11.79-11.86
Net Income From Continuing Operations-9.23-12.35-7.22-11.26-13.94-13.43-11.79-11.86
Net Income-9.24-12.35-7.22-11.26-13.95-13.44-11.79-11.86
EPS (Recurring)-0.14-0.18-0.11-0.17-0.21-0.20-0.21-0.25
EPS (Basic, Before Extraordinaries)-0.14-0.18-0.11-0.17-0.21-0.20-0.21-0.25
EPS (Diluted)-0.14-0.18-0.11-0.17-0.21-0.20-0.21-0.25
EBITDA-9.39-12.63-7.60-11.75-14.55-14.15-12.48-12.50
Non-Operating Income (Expense)0.380.510.610.720.830.950.790.75
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.921.661.261.381.681.361.201.25
Price To Sales Ratio175.03210.91321.82274.99383.80355.25350.52181.61
Gross Margin-113.46-439.028.23-86.67-89.26-109.1736.4238.79
Operating Margin-9,245.19-31,341.46-3,220.99-9,978.33-12,212.40-13,194.50-8,325.83-7,636.97
Net Margin-8,882.69-30,124.39-2,972.43-9,386.67-11,528.10-12,330.28-7,809.93-7,188.48
Shares Outstanding68.5068.3768.3167.0966.5366.5366.5248.73
Market Capitalization61.83110.75189.28137.04209.56208.89288.69124.29

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments58.3091.7574.82105.27140.82130.9810.2011.458.23
Short Term Receivables0.181.170.890.770.540.320.200.170.08
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets1.642.131.705.254.772.060.951.141.17
Total Current Assets60.1395.0577.41111.28146.13133.3611.3512.779.47
Net Property, Plant & Equipment1.212.072.953.523.180.971.581.302.43
Total Investments and Advances0.000.000.000.000.000.000.000.000.00
Long-Term Note Receivable---0.000.142.170.97--
Other Assets0.550.071.281.390.240.400.160.100.39
Total Assets61.8897.1981.64116.19149.68136.9014.0614.1712.28
Short Term Debt Incl. Current Port. of LT Debt0.730.710.690.680.550.860.870.001.33
Accounts Payable8.094.821.971.961.441.370.660.660.83
Other Current Liabilities7.587.907.785.184.573.893.262.301.79
Total Current Liabilities16.3913.4310.447.816.566.124.782.973.95
Long Term Debt0.100.811.462.042.570.010.860.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.440.131.121.83
Total Liabilities16.5014.2411.909.859.136.575.784.095.78
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.006E-056E-056E-05
Common Equity45.3982.9569.74106.34140.56130.338.2810.086.51
Total Shareholders Equity45.3982.9569.74106.34140.56130.338.2810.086.51
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity45.3982.9569.74106.34140.56130.338.2810.086.51
Total Liabilities & Stockholders Equity61.8897.1981.64116.19149.68136.9014.0614.1712.28
Book Value Per Share0.661.251.562.383.353.540.962.638.87
Tangible Book Value Per Share0.661.251.562.383.353.540.962.638.87
Full-Time Employees313332262312141317
Price to Book Ratio2.054.280.850.541.795.081.291.202.97
Return on Assets-57.65-50.81-41.90-29.11-19.74-25.58-116.29-124.44-88.58
Return on Equity-71.45-59.51-47.07-31.35-20.89-27.86-178.73-198.44-189.59
Return on Invested Capital-100.79-54.24-58.21-35.71-19.77-14.81-179.51-163.24-382.82
Quick Ratio3.677.087.4114.2522.2821.792.374.302.40
Current Ratio3.677.087.4114.2522.2821.792.374.302.40

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-40.05-45.85-45.43-41.44-38.70-28.29-19.31-16.41-16.46
Depreciation0.890.900.400.400.240.450.470.490.86
Other Funds (Non Cash)4.664.844.163.595.036.593.181.562.15
Funds from Operations-34.50-40.10-40.87-37.45-33.44-21.25-15.66-14.36-13.45
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-6.352.183.176.57-0.38-1.79-0.651.090.25
Cash from Operating Activities-40.85-37.92-37.69-30.89-33.82-23.04-16.31-13.27-13.20
Capital Expenditures-0.06-0.04-0.08-0.58-1.01-0.20-0.21-0.07-0.01
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00-
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.000.03
Purchase or Sale of Investments36.501.3913.8136.7839.04-131.240.000.000.00
Purchase of Investments-29.93-71.86-23.56-70.08-91.23-174.380.000.00-0.03
Sale Or Maturity of Investments66.4373.2537.37106.86130.2743.140.000.000.03
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.110.000.000.000.00
Cash from Investing Activities36.441.3413.7336.2038.15-131.45-0.21-0.070.02
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock2.832.5853.780.000.0735.45137.3212.1217.78
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock2.832.5853.780.000.0735.45137.3212.1217.78
Proceedsfrom Stock Options0.150.0053.410.000.0034.19112.308.8216.17
Issuance or Reduction of Debt, Net0.000.000.000.000.000.000.000.00-1.38
Change in Long Term Debt0.000.000.000.000.000.000.000.00-1.38
Issuance of Long Term Debt0.000.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.00-1.38
Net Financing Active Other Cash Flow0.000.000.000.000.000.00-0.01-0.040.00
Other Financing Activities Uses0.000.000.000.000.000.00-0.01-0.040.00
Cash from Financing Activities2.832.5853.780.000.0735.45137.3112.0816.40
Exchange Rate Effect--------0.00
Net Change in Cash-1.59-34.0029.825.314.40-119.04120.79-1.263.23
Free Cash Flow-40.92-37.97-37.77-31.47-34.83-23.25-16.53-13.34-13.20
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments34.5246.0658.3060.5970.9679.89
Short Term Receivables0.190.190.180.250.530.41
Inventories0.000.000.000.000.000.00
Other Current Assets0.881.091.640.962.212.42
Total Current Assets35.5947.3460.1361.8073.7082.71
Net Property, Plant & Equipment0.810.991.211.431.641.84
Total Investments and Advances0.000.000.000.000.000.00
Other Assets0.930.840.550.550.400.26
Total Assets37.3349.1761.8863.7875.7484.81
Short Term Debt Incl. Current Port. of LT Debt0.460.650.730.730.720.72
Accounts Payable3.995.488.092.446.013.63
Other Current Liabilities6.358.347.5811.549.948.95
Total Current Liabilities10.8014.4616.3914.7116.6713.29
Long Term Debt0.000.000.100.280.460.64
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.00
Total Liabilities10.8014.4616.5014.9917.1313.93
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity26.5334.7145.3948.7958.6170.88
Total Shareholders Equity26.5334.7145.3948.7958.6170.88
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity26.5334.7145.3948.7958.6170.88
Total Liabilities & Stockholders Equity37.3349.1761.8863.7875.7484.81
Book Value Per Share0.390.510.660.730.881.07
Tangible Book Value Per Share0.390.510.660.730.881.07
Full-Time Employees--31---
Price to Book Ratio2.052.443.862.342.962.52
Return on Assets-70.84-66.82-57.65-79.61-71.96-61.51
Return on Equity-94.08-84.79-71.45-102.71-91.93-74.15
Return on Invested Capital-34.80-35.57-15.86-22.94-23.60-18.78
Quick Ratio3.303.273.674.204.426.22
Current Ratio3.303.273.674.204.426.22

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-9.23-12.35-7.22-11.26-13.94-13.43
Depreciation0.220.220.220.220.230.23
Other Funds (Non Cash)0.861.571.101.131.381.23
Funds from Operations-8.15-10.56-5.89-9.90-12.33-11.98
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-3.61-1.73-0.08-0.934.00-0.82
Cash from Operating Activities-11.77-12.29-5.97-10.83-8.33-12.79
Capital Expenditures-0.040.000.00-0.02-0.030.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments12.313.2610.7510.18-4.96-14.58
Purchase of Investments-1.30-12.57-6.72-9.34-19.98-35.81
Sale Or Maturity of Investments13.6215.8317.4719.5215.0321.23
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities12.273.2610.7510.16-4.98-14.58
Cash Dividends Paid0.000.000.000.000.000.00
Change in Capital Stock0.150.102.550.030.000.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.150.102.550.030.000.00
Proceedsfrom Stock Options0.150.000.000.000.000.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities0.150.102.550.030.000.00
Net Change in Cash0.65-8.937.33-0.65-13.31-27.38
Free Cash Flow-11.81-12.29-5.97-10.85-8.35-12.79

Revenue breakdown

Total Biological Products, (No Diagnostic Substances) revenue2024: 683.00K 2025: 593.00K
United States2024: 683.00K 2025: 593.00K

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3016.80%12.3M73.0M660.40K
2026-10-1516.60%12.1M73.0M833.08K
2026-09-3016.54%12.1M73.0M1.09M
2026-09-1516.86%12.3M73.0M1.25M
2026-08-3116.02%11.7M73.0M1.42M
2026-08-1416.31%11.9M73.0M1.55M
2026-07-3117.50%12.2M69.7M1.53M
2026-07-1517.35%12.1M69.7M1.41M
2026-06-3020.49%12.8M62.5M1.20M
2026-06-1525.80%16.1M62.6M1.02M
2026-05-2928.97%18.1M62.6M782.10K
2026-05-1528.79%18.0M62.6M696.96K
2026-04-3029.46%18.4M62.4M725.39K
2026-04-1529.40%18.3M62.3M1.07M
2026-03-3128.79%17.9M62.2M1.09M
2026-03-1327.98%17.4M62.2M1.20M
2026-02-2728.41%17.7M62.2M1.24M
2026-02-1328.89%18.0M62.2M1.24M
2026-01-3028.01%17.2M61.4M1.21M
2026-01-1526.42%16.2M61.4M892.36K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call0.500.000.750.3525.0191550.000.982-0.0080.000
call1.000.000.050.052.21692.000.000.321-0.0050.000
call1.500.000.050.053.7532,2360.000.232-0.0080.000
call2.000.001.000.104.9053560.000.204-0.0090.000
call2.500.000.200.035.3201,6960.000.188-0.0090.000
call5.000.000.750.037.1271960.000.160-0.0110.000
call7.500.001.800.218.43460.000.000.151-0.0130.000
put0.500.001.000.050.00015.000.00-0.018-0.0080.000
put1.000.000.750.1513.5993.000.00-0.682-0.0060.000
put1.500.251.250.6515.0470.000.00-0.768-0.0080.000
put2.000.751.750.6915.9830.000.00-0.796-0.0090.000
put2.501.252.250.0014.7720.000.00-0.812-0.0090.000
put5.002.206.500.000.0000.000.00-0.839-0.0120.000
put7.505.807.700.000.0000.000.00-0.849-0.0130.000

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-10-273Initial statement of beneficial ownership of securities2026-10-23SEC
2026-10-278-KCurrent report2026-10-22SEC
2026-10-228-KCurrent report2026-10-22SEC
2026-09-148-KCurrent report2026-09-14SEC
2026-08-26DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-08-26DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-08-26SEC
2026-08-14PRE 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-08-14SEC
2026-08-118-KCurrent report2026-08-11SEC
2026-08-1110-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-07-27SCHEDULE 13G/ASEC
2026-07-21S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-07-164Statement of changes in beneficial ownership of securities2026-07-14SEC
2026-07-164Statement of changes in beneficial ownership of securities2026-07-14SEC
2026-07-168-KCurrent report2026-07-14SEC
2026-07-16424B5SEC
2026-06-224Statement of changes in beneficial ownership of securities2026-06-18SEC
2026-06-224Statement of changes in beneficial ownership of securities2026-06-18SEC
2026-06-154Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-154Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-154Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-154Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-154Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-118-KCurrent report2026-06-11SEC
2026-06-038-KCurrent report2026-06-03SEC
2026-05-298-KCurrent report2026-05-27SEC
2026-05-198-KCurrent report2026-05-19SEC
2026-05-148-KCurrent report2026-05-14SEC
2026-05-1410-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-04-284Statement of changes in beneficial ownership of securities2026-04-27SEC
2026-04-283Initial statement of beneficial ownership of securities2026-04-27SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-071.05M200
2026-0666.49K200
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
VANGUARD CAPITAL MANAGEMENT LLC4.24%
Laurion Capital Management LP3.98%
PFIZER INC3.53%
FRANKLIN RESOURCES INC1.76%
BlackRock, Inc.1.42%
BLAIR WILLIAM & CO/IL1.18%
GEODE CAPITAL MANAGEMENT, LLC1.08%
JANE STREET GROUP, LLC0.89%
GoalVest Advisory LLC0.88%
VANGUARD FIDUCIARY TRUST CO0.60%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND3.03%
VANGUARD EXTENDED MARKET INDEX FUND1.11%
Fidelity Small Cap Index Fund0.90%
Franklin Biotechnology Discovery Fund0.57%
Fidelity Extended Market Index Fund0.49%
VANGUARD RUSSELL 2000 INDEX FUND0.48%
iShares Micro-Cap ETF0.32%
Schwab Small-Cap Index Fund0.20%
Fidelity Total Market Index Fund0.15%
Fidelity Series Total Market Index Fund0.13%

OakChart. CRDF. Cached 15 minutes.